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7 Abstract As part of its Medical Technology Evaluation
8 Programme, the National Institute for Health and Care
9 Excellence (NICE) invited a manufacturer to provide
10 clinical and economic evidence for the evaluation of the
11 Debrisoft monofilament debridement pad for use in acute
12 or chronic wounds. The University of Birmingham and
13 Brunel University, acting as a consortium, was commis-
14 sioned to act as an External Assessment Centre (EAC) for
15 NICE, independently appraising the submission. This
16 article is an overview of the original evidence submitted,
17 the EAC’s findings and the final NICE guidance issued.
18 The sponsor submitted a simple cost analysis to estimate
19 the costs of using Debrisoft to debride wounds compared
20 with saline and gauze, hydrogel and larvae. Separate
21 analyses were conducted for applications in home and
22 applications in a clinic setting. The analysis took an UK
23 National Health Service (NHS) perspective. It incorporated
24 the costs of the technologies and supplementary technolo-
25 gies (such as dressings) and the costs of their application by
26 a district nurse. The sponsor concluded that Debrisoft was
27 cost saving relative to the comparators. The EAC made
28 amendments to the sponsor analysis to correct for errors
29 and to reflect alternative assumptions. Debrisoft remained
30 cost saving in most analyses and savings ranged from £77
31 to £222 per patient compared with hydrogel, from £97 to
32 £347 compared with saline and gauze, and from £180 to
33 £484 compared with larvae depending on the assumptions
34 included in the analysis and whether debridement took
35place in a home or clinic setting. All analyses were
36severely limited by the available data on effectiveness, in
37particular a lack of comparative studies and that the
38effectiveness data for the comparators came from studies
39reporting different clinical endpoints compared with
40Debrisoft. The Medical Technologies Advisory Com-
41mittee made a positive recommendation for adoption of
42Debrisoft and this has been published as a NICE medical
43technology guidance (MTG17). 4
4546
Key Points for Decision Makers 47
49
50
51Debrisoft is convenient and easy to use, is well-
52tolerated by adults and children, and can result in
53quicker debridement of chronic or acute wounds
54with fewer nurse visits needed than other
55debridement methods. Debridement is an important
56component of standard wound care management, as
57described in clinical guidelines on pressure ulcers
58[National Institute for Health and Care Excellence
59(NICE) clinical guideline 179] and diabetic foot
60problems (NICE clinical guideline 119).
61Debrisoft is estimated to be cost saving for
62complete debridement compared to other methods
63such as hydrogel, gauze and bagged larvae. 4
65
661 Introduction
67The National Institute for Health and Care Excellence
68(NICE) produces evidence-based medical technologies
69guidance with the overall aim of evaluating, and where
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70 appropriate encouraging, the adoption of novel and inno-
71 vative medical devices and diagnostics within the National
72 Health Service (NHS) in England. Manufacturers or dis-
73 tributors of potentially eligible technologies notify their
74 products to NICE’s Medical Technologies Evaluation
75 Programme (MTEP). Technologies are selected for evalu-
76 ation by MTEP if they have the potential to offer signifi-
77 cant clinical benefits to patients and the NHS or reduce the
78 cost compared with current standard practice. Guidance is
79 produced after clinical and cost evidence submitted by the
80 sponsor is independently assessed by an External Assess-
81 ment Centre (EAC) and after a public consultation period.
82 Devices and diagnostic tools with more complex value
83 propositions can be routed for evaluation through other
84 NICE programmes such as the Diagnostics Assessment
85 Programme or Technology Appraisals. Campbell and
86 Campbell (2012) describe the methods of MTEP in more
87 detail [1].This article presents a summary of the EAC
88 report for the Debrisoft monofilament debridement pad
89 (Lohmann & Rauscher GmbH & Co. KG, Neuwied, Ger-
90 many) for use in acute or chronic wounds. It is part of a
91 series of NICE Medical Technology Guidance summaries
92 being published in Applied Health Economics and Health
93 Policy [2, 3].
94 2 Background to the Condition and its Treatment
95 Skin wounds are a very common condition and can be
96 acute or chronic. Acute wounds occur from cuts, burns,
97 abrasions or pressure on the skin. Some acute wounds
98 become chronic, particularly if there is underlying pathol-
99 ogy, e.g. diabetes mellitus or poor venous drainage.
100 Chronic wounds include pressure ulcers, diabetic foot
101 ulcers, and venous and arterial leg ulcers.
102 In the UK in 2008, approximately 200,000 people had
103 chronic wounds. These wounds include leg, pressure and
104 foot ulcers [4]. Leg ulcers affect 1 in 500 people, although
105 this rises sharply with an increase in age, to 1 in 50 in those
106 over the age of 80 years [5]. In the UK, the annual inci-
107 dence for foot ulcers among people with diabetes is 2–5 %,
108 with the annual incidence of amputation being 0.25–1.8 %
109 [6]. Approximately 10 % of all leg ulcers are caused by
110 arterial ulcers.
111 Lymphoedema is a chronic condition that is charac-
112 terised by oedema. Primary lymphoedema, an inherited
113 condition, occurs in 1 in 10,000 people and mainly affects
114 the legs, whereas secondary lymphoedema, caused by an
115 injury to the lymph system, affects approximately 100,000
116 people in total in the UK [7] and can affect the legs and
117 arms, depending on cause.
118 In any given year, just under half a million people in the
119 UK will developing at least one pressure ulcer, usually
120people with an underlying health condition. Around 1 in 20
121people who are admitted to hospital with an acute (sudden)
122illness will develop a pressure ulcer [8].
123Debridement is the removal of devitalised, contaminated
124or foreign material from the surface of a wound with the
125intension to expose healthy tissue. The main methods of
126debridement are mechanical, sharp, larvae (loose or bag-
127ged), autolytic, enzymatic or surgical. These methods have
128different characteristics, speeds of conduct, advantages and
129disadvantages, and can be conducted by different groups of
130healthcare professionals (see Table 1). It is widely believed
131that wound healing is enhanced by the practice of
132debridement, but there is little conclusive proof. An early
133health technology assessment found no randomised con-
134trolled trials (RCTs) comparing debridement to no
135debridement in chronic wounds [9], but a more recent
136review on debridement methods has shown there may be
137some RCTs [10], although the descriptions of the primary
138study control groups in this review are unclear. A recent
139Cochrane review on debridement in diabetic foot ulcers has
140claimed that direct evidence on debridement versus no
141debridement is lacking [11]. There have been no large,
142good-quality RCTs of debridement versus no debridement
143in any acute or chronic wounds, so whether it is beneficial
144or not in acute or chronic wounds is unclear. RCTs found
145include one on surgical debridement in chronic venous
146ulcers which showed that 16 % of 28 ulcers had complete
147healing in the debridement group compared with 4.3 % of
14827 ulcers in the control group [12]. Another on surgical
149debridement [13] found that 21 of 22 (95 %) ulcers treated
150with surgical debridement had completely healed within
1516 months, compared with 19 of 24 (79 %) in the conser-
152vative care group. An early RCT on debridement versus no
153debridement in acute wounds (gunshot) found that slightly
154more patients in the debridement group (4 of 89) got
155wound infections than those in the control group (2 of 74)
156[14]. A recent US cohort study of a large number of
157patients with a variety of mainly chronic wounds found that
158those wounds receiving more frequent debridement had
159faster healing rates on average [15]. However, the results
160may be confounded by a variety of factors such as patient
161characteristics, nursing care experienced and debridement
162methods used. Nevertheless, it seems to be generally
163accepted by most wound care practitioners that debride-
164ment is mostly beneficial.
165With regard to effectiveness of debridement, good
166comparative evidence does exist on the comparators, e.g. is
167a large cohort study was published recently of 312,744
168wounds (154,664 patients, median age 69 years) looking at
169frequency of debridement and time to heal [15]. The
170debridement methods included autolytic, enzymatic,
171mechanical, surgical and biosurgical (larvae). The wound
172types were a wide variety of chronic wounds. The study
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173found that more debridements per wound resulted in faster
174healing times. A Cochrane review of debridement of dia-
175betic foot ulcers [11] included RCTs on larvae compared
176with hydrogel [16] and hydrogel compared with gauze/s-
177tandard care [17–19]. A Cochrane review of debridement
178of surgical wounds [20] included RCTs of hydrogel com-
179pared with gauze [21, 22].
1803 The Decision Problem
1813.1 Population
182The target population was adults or children requiring
183debridement of an acute or chronic wound in a community-
184based setting. The skin could be intact (closed wounds) or
185non-intact (open wounds). The sponsor evaluated adults
186with chronic wounds and did not investigate the subgroup
187of open and closed wounds. There was a considerable lack
188of clarity over normal debridement practice in a standard
189NHS community setting.
1903.2 Intervention
191The intervention was Debrisoft monofilament debride-
192ment pad, which is a square pad measuring 10 9 10 cm
193that has monofilament polyester fibres projecting from the
194wound contact side, making it feel soft and fleecy. The pad
195is used when moistened with water and is gently rubbed
196over wound or skin surfaces, and is intended to facilitate
197the removal of dead or damaged tissue, etc. The claimed
198benefits of Debrisoft include reduction in pain, improved
199acceptability, faster treatment and healing, reduced risks of
200trauma to healthy tissue, and of bleeding, reduced time and
201resources needed, lower costs and shorter waiting times,
202more effective debridement, improved patient concordance
203and avoidance of ongoing costs relating to specialist
204methods of debridement.
2053.3 Comparators
206The scope comparators were hydrogels or other autolytic
207dressings, or cleansing with gauze. The sponsor also
208evaluated the use of larvae. It was unclear whether the
209gauze use was wet to dry debridement or just wet
210cleansing.
2113.4 Outcomes
212Outcomes, including surrogate outcomes, listed in the
213scope included wound healing, quality of life, time to
214complete debridement, number of debridements required,
215number of dressings required, types of dressings requiredT
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216 and the need to refer to a tissue viability nurse or hospital
217 specialist clinic. Adverse effects included pain, wound
218 infections, cellulitis and trauma to healthy tissue.
219 4 Review of the Clinical and Economic Evidence
220 The sponsor submitted clinical and economic evidence
221 based on the scope issued by NICE. The economic evi-
222 dence included a de novo economic model. The EAC
223 critically appraised the submission and carried out addi-
224 tional analyses to evaluate the outcomes identified in the
225 scope.
226 4.1 Clinical Effectiveness Evidence
227 4.1.1 Sponsor’s Review of Clinical Effectiveness Evidence
228 The sponsor submitted 51 studies in the qualitative syn-
229 thesis. However, many of these were single case studies or
230 testimonials, some within larger documents. They included
231 eight journal articles, 28 conference posters and two
232 advertising reports sponsored by the company that included
233 multiple case studies. There were several multiple patient
234 case series submitted. Bahr et al. [23] and Mustafi et al.
235 [24] compared the overall mean time of each debridement
236 session, using the Debrisoft pad, with hydrogel, gauze and
237 surgical debridement in 60 patients. Gray et al. [25]
238 described a case series of 18 patients that evaluated which
239 types of slough and necrotic tissue benefit most from
240 debridement with the Debrisoft pad. Haemmerle et al.
241 [26] described a case series of 11 patients with chronic
242 wounds from two hospitals. Johnson et al. [27] described a
243 two-centre observational study that compared the effec-
244 tiveness of the Debrisoft pad with other non-specified
245 debridement methods. Ten patients were recruited from
246 each centre. Stephen-Haynes and Callaghan [28] evaluated
247 the use of the Debrisoft pad by 40 tissue viability nurses,
248 over a 12-week period, on a wound or hyperkeratosis.
249 4.1.2 Critique of Clinical Effectiveness Evidence
250 As the claimed benefits for Debrisoft were all compara-
251 tive statements, only evidence with comparators was
252 evaluated. These were journal articles by Bahr et al. [23]
253 and Johnson et al. [27], and conference posters by Cal-
254 laghan and Stephen-Haynes [29], Collarte [30], Mustafi
255 et al. [24], Pietroletti et al. [31] and Wiser [32]. The
256 characteristics of these studies are in Table 2.
257 An attempt was made to match the claimed benefits of
258 Debrisoft to the comparative evidence available. Table 3
259 shows all of the numerical comparative results found.
260 Some of the included studies reported comparative results
261narratively. Wiser [32] reported reduction of pain, more
262effective debridement and improved acceptability with
263Debrisoft compared with saline soaks. Collarte [30]
264reported a decreased time to treat with Debrisoft com-
265pared with standard treatment (not otherwise specified) and
266that autolytic debridement took significantly longer. Col-
267larte also reported that Debrisoft removed more devi-
268talised tissue and hyperkeratosis more quickly. Callaghan
269and Stephen-Haynes [29] reported a reduction in wound
270care visits for Debrisoft, but it was not clear what the
271comparator was. They also reported that there were sig-
272nificant differences compared with gauze and sharp
273debridement. Pietroletti et al. [31] reported that Debrisoft
274was not as expensive as current debridement methods (not
275otherwise specified).
276The comparative evidence suggested that Debrisoft
277was associated with less pain, improved acceptability by
278patients, decreased time to treat, reduction in wound care
279visits, more removal of devitalized tissue and more effec-
280tive debridement than standard treatment, previous meth-
281ods (not specified), gauze, autolytic, enzymatic or sharp/
282scalpel debridement. There was no comparative evidence
283on larvae found. It can be seen that there is no comparative
284information on most of the claimed benefits, particularly
285healing rates, compared with the comparators listed in the
286scope and to larvae (see Table 3). There was no useful
287evidence on the rate of wound healing or wound infections.
288There was no information on the mean number of appli-
289cations required with Debrisoft to achieve complete
290debridement.
291No comparative results on adverse events were pre-
292sented by the sponsor. It is currently unclear if use of
293Debrisoft is associated with higher rates of wound
294infections than the comparators of gauze, hydrogel or lar-
295vae. It is also unclear if use of Debrisoft is associated with
296higher or lower rates of pain in the patient than the com-
297parators of gauze, hydrogel or larvae. The NICE expert
298advisers have not voiced a clear opinion about adverse
299events with the use of Debrisoft compared with the
300comparators of gauze, hydrogel or larvae.
3014.2 Economic Evidence
3024.2.1 Sponsor’s Economic Submission
303The sponsor conducted a systematic search of economic
304evidence from the literature but this did not identify any
305studies reporting data on the costs or cost effectiveness of
306Debrisoft. In the absence of an appropriate published
307analysis, the sponsor submitted a de novo analysis using a
308simple cost model executed in Microsoft Excel. The
309model estimated the cost and resource consequences of
310Debrisoft used in a community setting compared with
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311 hydrogel, gauze and larvae. Separate analyses were con-
312 ducted for applications in home and clinic settings. All
313 analyses were based on an NHS perspective. No distinction
314 was made between adults and children, or between chronic
315 and acute wounds.
316 The stated time horizon of the analysis was to complete
317 debridement. The clinical pathway reflected in the model
318 included the following five stages: (1) an assessment of the
319 skin and wound by a district nurse; (2) ordering the
320 debridement agent if not available to the district nurse
321 immediately; (3) application of the debridement agent by a
322 district nurse; (4) re-assessment of the wound; and (5)
323 further applications of the debridement agents until
324 debridement is judged to be complete.
325 The effectiveness data used in the analysis came from
326 three separate sources (see Table 4). Data on the mean
327 number of applications to achieve wound healing from a
328 published randomised trial were used to inform the effec-
329 tiveness of larvae and hydrogel [33, 34]. The effectiveness
330 of Debrisoft was based on the percentage of wounds
331 completely debrided after three applications as reported in
332 the case series study by Bahr et al. [23]. This reported that
333 77 % of wounds were completely debrided with Debrisoft
334 after three applications. For gauze, the effectiveness data
335 were based on clinical opinion of the number of applica-
336 tions required to achieve complete debridement. A sum-
337 mary of the effectiveness data used in the model is
338presented in Table 4. The model did not include adverse
339events associated with any of the technologies.
340Given the differences in outcome measures used to inform
341clinical effectiveness in the model, particularly the lack of
342data on the mean number of applications for Debrisoft to
343achieve debridement, the sponsor employed a ‘stopping rule’
344for Debrisoft in the analysis. This assumed that if the wound
345was not completely debrided after three applications of
346Debrisoft, patients would switch to the use of hydrogel for
347complete debridement. No stopping rule was employed for
348the other debridement agents.
349Resource use included the debridement agents (De-
350brisoft, hydrogel, gauze and larvae), supplementary
351technologies (cover dressings: film and absorbent dress-
352ings; dressing packs) and district nurse visits (at home or
353clinic). The amount of debridement agents required was
354based on the amount needed to debride a wound of
35510 9 10 cm. The cost of larvae was based on the costs of
356loose larvae and obtained directly from a supplier. The cost
357of hydrogel was based on the median cost of all formula-
358tions listed in the British National Formulary (BNF) [35].
359Unit costs were obtained from published sources and were
360expressed in 2012–2013 Great Britain pounds sterling
361(reported in Table 5).
362The number of visits by a district nurse required to apply
363the debridement agent varied according to setting (clinic or
364home) and comparator. The number and length of district
Table 4 Amount and unit cost of each debridement product
Comparator Number of applications to complete debridement Cost per application
n Source Cost (£) Source
Debrisoft 3 Bahr et al. [23] 6.19 BNF 2012 [35] (A5.5.3)
Loose larvae 1.45 Soares et al. [36] 175.00 Biomonde, data on file, 2013
Bagged larvae 1.45 Soares et al. [36] 295.00 Biomonde, data on file, 2013
Hydrogel 9.2 Soares et al. [36] 2.03 BNF 2012 [35] (median price) (A5.2.1)
Gauze 12 Clinical opinion 0.39 BNF 2012 [35] (A5.7.2)
BNF British National Formulary
Table 5 Summary of unit cost estimates in the sponsor’s economic model
Resource Unit cost (£) Source
District nurse (15 min—clinic visit) 12.75 PSSRU costs for community nurse—sponsor calculation
District nurse (15 min—home visit) 24.25 PSSRU costs for home visit community nurse—sponsor calculation
District nurse (15 min—clinic visit) 14.50 PSSRU costs for community nurse—EAC calculation
District nurse (15 min—home visit) 17.50 PSSRU costs for home visit by community nurse—EAC calculation
Dressing pack (all comparators/settings) 0.60 BNF 2012 [35]
Secondary dressing (for larvae and gauze) 0.17 BNF 2012 [35]
Secondary dressing (for hydrogel) 1.02 BNF 2012 [35]
BNF British National Formulary, EAC External Assessment Centre, PSSRU Personal And Social Services Research Unit
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365 nurse visits were based on expert opinion. Gauze (clinic
366 and home settings) and hydrogel (clinic setting only) are
367 assumed to be available to the nurse immediately and
368 require a total of two visits for the first application (one to
369 assess the wound and apply the debridement product; the
370 second to reassess the wound and reapply the product if
371 needed) plus one visit for each subsequent application. It
372 was assumed that hydrogel would require ordering by the
373 district nurse in the home setting following the initial
374 assessment, similar to larvae in both the home and clinic
375 settings. Therefore, additional visits are included for the
376 first application of hydrogel in the home setting and for the
377 first and all sequent applications of larvae in the home and
378 clinic settings. All district nurse visits were assumed to last
379 15 min.
380 The sponsor conducted deterministic sensitivity analy-
381 ses on the number of debridement applications, the number
382 of district nurse visits and unit costs of debridement agents
383 (all increased and decreased by an arbitrary 20 %). Prob-
384 abilistic analyses were not presented.
385 The baseline results of the sponsor’s analysis are pre-
386 sented in Table 6. Debrisoft was cost saving compared
387 with all three comparators in both the home and clinic
388 settings. Debrisoft remained cost saving in all sensitivity
389 analyses.
390 4.2.2 Critique of Economic Evidence
391 Overall, the pathway of care reflected in the sponsor’s
392 economic model appeared to be appropriate. The time
393 horizon of the analysis was until debridement rather than to
394 wound healing, which may have been a more meaningful
395 endpoint as it could reflect that some wounds will require
396 multiple debridements. Time to wound healing has been
397used as the endpoint in previous clinical trials of debride-
398ment, including the main source of effectiveness used in
399the sponsor’s analysis for hydrogel and larvae [33].
400The main drivers of the cost analysis were the number of
401applications required to debride the wound and number of
402visits required per application for each product. Although
403the stated time horizon was until complete debridement,
404the effectiveness data used for two of the comparators in
405the analysis (larvae and hydrogel) did not reflect this
406endpoint. The data on the number of applications for larvae
407and hydrogel came from a randomised clinical trial of the
408products with a primary endpoint of wound healing and an
409average follow-up of 1 year. The data from these studies
410used in the analysis reflected the average number of
411applications until wound healing rather than the number of
412applications to achieve complete debridement. The effec-
413tiveness data used for Debrisoft were not comparable and
414based on the percentage of wounds successfully debrided
415after three applications at 12 days of follow-up from the
416case series study [23]. This study found that 77 % of
417wounds were completely debrided at 12 days; however,
418following clarification, the sponsor confirmed that this
419endpoint was not pre-specified in the analysis plan for the
420trial. This lack of information from a direct comparison or
421network meta-analysis for the main effectiveness data used
422in the economic analysis is likely to lead to bias in the
423comparison of the number of applications for each of the
424products; however, it is difficult to judge the likely impact
425of this on the results.
426To compensate for the lack of comparability in the
427effectiveness outcomes used in the analysis, the sponsor
428employed a ‘stopping rule’ for Debrisoft. The advice
429from a NICE clinical expert was that two to three appli-
430cations of Debrisoft would usually be required to debride
Table 6 Results of the
economic analyses (in
2012/2013 British pounds; £)
Saline and gauze Hydrogel Larvae Debrisoft
Home Clinic Home Clinic Home Clinic Home Clinic
Sponsor’s base case
Cost of debridement 330 180 308 165 351 306 162 83
Debrisoft incremental cost -168 -97 -147 -82 -190 -223
EAC corrected analysis
Cost of debridement 242 203 233 183 325 313 145 106
Debrisoft incremental cost -98 -97 -88 -77 -180 -207
EAC amendments
Cost of debridement 621 291 544 238 613 514 333 139
Debrisoft incremental cost -288 -152 -211 -99 -280 -375
Committee-requested analysis
Cost of debridement 621 291 497 238 744 623 275 139
Debrisoft incremental cost -347 -152 -222 -99 -469 -484
EAC External Assessment Centre
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431 a hard eschar, and one application for a sloughy wound.
432 Based on this advice, the assumptions around the number
433 of applications of Debrisoft per debridement may be
434 reasonable.
435 The time taken by the district nurse visit was based on
436 advice from clinical experts and differs to estimates
437 reported in a randomised trial of hydrogel and larvae in
438 which the length of appointments was measured directly
439 [36]. This trial reported the average duration of clinic visits
440 to be 22 and 40 min for home visits.
441 The costs of larvae included in the analysis are based on
442 the costs of loose larvae. Advice from a NICE clinical
443 advisor was that bagged larvae would be used in UK
444 clinical practice. This would have the effect of making
445 larvae more expensive relative to Debrisoft.
446 Further alternative feasible assumptions around the
447 amount and costs of dressings could have been included in
448 the sponsor’s analysis. Additional film and absorbent
449 dressings would not be required prior to debridement,
450 specifically at the first appointment if the debridement
451 product has to be ordered by the district nurse. Also, the
452 unit costs for these dressings, gauze and hydrogels were
453 based on the median unit costs for each type of technology
454 listed in the BNF. We considered that, given the assump-
455 tion of equal efficacy in the model, it would be appropriate
456 to use the lowest unit cost for each technology to reflect
457 cost-effective practice.
458 4.2.3 Supplementary Economic Analyses Conducted
459 by the External Assessment Centre
460 Upon review of the economic model, the EAC identified
461 some errors in the sponsor’s analysis. These included the
462 incorrect implementation of the stopping rule for
463 Debrisoft and a miscalculation in the unit costs of a dis-
464 trict nurse visit at home. The estimates of the district nurse
465 costs appear to have come from a misunderstanding
466regarding the apportionment of travel costs and the unit
467costs for nurses with qualifications in the original esti-
468mates. The results of the cost analysis after correcting these
469errors are presented in Table 6 (‘EAC corrected analysis’).
470Further changes were made by the EAC to reflect
471alternative assumptions in the economic model. Firstly, the
472costs of larvae were amended to the bagged variety. Sec-
473ondly, the costs of additional dressings when patients did
474not undergo debridement were removed. Thirdly, the time
475taken for each district nurse visit was amended to that
476reported in the published trial of hydrogel and larvae [36].
477Finally, the unit costs of dressings, gauze and hydrogels
478were amended to the cheapest listed in the BNF. The
479impact of all of these changes on the results is shown in
480Table 6 (‘EAC amendments’). The use of the costs of
481bagged larvae led to a substantial increase in the costs of
482this comparator relative to Debrisoft. The amendments to
483the nursing time also had an impact on the results,
484increasing the estimated cost savings for Debrisoft rela-
485tive to gauze and hydrogel, particularly in the home setting.
486The other amendments to the dressings had only a marginal
487impact.
488The EAC also conducted further exploratory analyses.
489These included removing the stopping rule from the analysis
490and a threshold analysis to assess how many applications of
491Debrisoft would be required for it to no longer be the
492cheapest option, keeping all other variables constant. The
493starting point for these analyses was the analysis after cor-
494recting for errors and employing alternative assumptions
495(‘EAC amendments’). We found that, without the stopping
496rule, Debrisoft would no longer be the cheapest alternative
497if more than nine applications were required. With the
498stopping rule, this decreased to seven applications (Table 7).
499Finally, the EAC requested sight of a further analysis to
500reflect some different assumptions, specifically: (1) an
501additional five nurse visits for each larvae application, each
502with an average duration of 15 min; (2) one home visit for the
Table 7 Threshold analysis of the number of applications of required for Debrisoft to not be cost saving (incremental costs presented
compared with next cheapest alternative—hydrogel)
Debrisoft applications Incremental cost (including switching after stopping rule)
(£)
Incremental cost (excluding switching after stopping rule)
(£)
Home Clinic Home Clinic
3 -211 -99 -377 -153
4 -158 -71 -283 -125
5 -104 -43 -230 v97
6 -51 -15 -176 -69
7 Not cost saving Not cost saving -123 -41
8 Not cost saving Not cost saving -69 -13
9 Not cost saving Not cost saving -16 Not cost saving
10 Not cost saving Not cost saving Not cost saving Not cost saving
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503 first application of Debrisoft (to reflect the assumption that
504 nurses have immediate access to Debrisoft at their first
505 home visit and there is no need to order it); and (3) only two
506 home visits for the first application of hydrogel (to reflect the
507 assumption that nurses have immediate access to hydrogel at
508 their first home visit and there is no need to order it). The
509 results are shown in Table 6 (‘Committee-requested analy-
510 sis’). The results showed that Debrisoft remained cost
511 saving using these alternative assumptions.
512 In summary, the sponsor concluded that Debrisoft is
513 cost saving for use in the debridement of wounds compared
514 with larvae, gauze and hydrogel. This result remained
515 robust to most analyses conducted by the EAC. Cost sav-
516 ings ranged from £77 to £222 per patient compared to
517 hydrogel, from £97 to £347 compared with saline and
518 gauze, and from £180 to £484 compared with larvae
519 depending on the assumptions included in the analysis and
520 whether applied in a home or clinic setting (see Table 6).
521 The results are driven largely by the requirement for fewer
522 appointments with Debrisoft than with hydrogel and
523 gauze in the analysis, and from cheaper product costs for
524 Debrisoft relative to larvae. All analyses are severely
525 limited by a lack of comparative data for Debrisoft
526 compared with hydrogel, larvae or gauze. The threshold
527 analysis indicates that Debrisoft is likely to be cost saving
528 for most applications for an endpoint of debridement.
529 5 NICE Guidance
530 5.1 Preliminary Guidance
531 The evidence submitted by the sponsor and the EAC’s
532 critique of this evidence was presented to the Medical
533 Technologies Advisory Committee who provided draft
534 recommendations relating to the Debrisoft monofilament
535 debridement pad following their meeting in December
536 2013. These were as follows [37]:
537 1. ‘‘The case for adopting the Debrisoft monofilament
538 debridement pad as part of the management of acute or
539 chronic wounds in the community is supported by the
540 evidence. The available evidence is limited, but the
541 likely benefits of using the Debrisoft pad on appropri-
542 ate wounds are that they will be fully debrided more
543 quickly, with fewer nurse visits needed, compared with
544 other debridement methods. In addition, the Debrisoft
545 pad is convenient and easy to use, and is well tolerated
546 by patients. Debridement is an important component of
547 standard woundcare management as described in
548 Pressure ulcers (NICE clinical guideline 29) [now
549 replaced by guideline 179] and Diabetic foot problems
550 (NICE clinical guideline 119)’’ [38, 39].
5512. ‘‘The Debrisoft pad is indicated for adults and children
552with acute or chronic wounds. The available evidence
553is predominantly in adults with chronic wounds
554needing debridement in the community. The data
555indicate that the device is particularly effective for
556chronic sloughy and hyperkeratotic wounds.’’
5573. ‘‘The Debrisoft pad is estimated to be cost saving for
558complete debridement when compared with other
559debridement methods. Cost savings per patient (per
560complete debridement) are estimated to be £99, £152
561and £484 compared with hydrogel, gauze and bagged
562larvae respectively in a community clinic and £222,
563£347 and £469 respectively in the home.’’
5645.2 Consultation Response
565During consultation, NICE received 26 consultation com-
566ments from six consultees. As a result of these comments,
567the technology description was improved and updated and
568the comparator types were clarified, but the recommenda-
569tions did not change significantly. Section 4.5 was updated
570to state that nurses and other healthcare professionals
571should only use Debrisoft after appropriate training in its
572indications and safe application.
5736 Key Challenges and Learning Points
574The Committee agreed with the EAC’s conclusions that there
575was a lack of good-quality comparative evidence. The EAC
576considered that there was insufficient robust evidence to
577demonstrate that Debrisoft is clinically more effective than
578other methods for wound healing and wound infections. It
579would be better to measure outcomes to wound healing because
580this is a clinically much more important outcome and there does
581not appear to be a strong correlation between achieving com-
582plete debridement and subsequent wound healing. In the
583VenUS II trial [33, 40], a significant difference in debridement
584but no difference in time to healing was found. The sponsor
585agreed that there was a lack of evidence on wound healing:
586‘‘the complete healing outcome would bring in all
587sorts of confounding variables and the comparison of
588the benefits between debriding alternatives would be
589lost in the impact of the variables to complete wound
590healing, i.e. the physiology of the patient, background
591disease, effect of arterial status etc.’’
592[41]
593Also, ‘‘The evidence base is not sufficient at this time to
594allow a meaningful analysis of costs or time to complete
595healing with debrisoft compared with other debridement
596methods in scope (hydrogel or other autolytic dressing, and
597cleansing with gauze)’’.
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598 The EAC noted that the available evidence is mainly in
599 adults with chronic wounds and accepted that there is little
600 evidence specific to children or the debridement of acute
601 wounds. The EAC also noted, from the limited available
602 evidence, that the Debrisoft pad is particularly suited to
603 the debridement of sloughy wounds with exudate and
604 hyperkeratotic skin.
605 The EAC’s decision to recommend Debrisoft was
606 based on an evaluation of complete debridement which
607 suggested that Debrisoft may be cheaper overall than
608 larvae, hydrogel and debridement with gauze (which is
609 apparently not used in the UK, according to NICE clinical
610 experts). The limited evidence available for Debrisoft
611 meant it was not possible to consider longer-term outcomes
612 such as time to healing, adverse events, hospital visits, etc.
613 There is no information on debridement methods currently
614 being used by nurses or other health professionals in the
615 community in the UK.
616 The EAC considered that an RCT of Debrisoft com-
617 pared with normal current practice in the community is
618 needed. We suggest that follow-up should be to wound
619 healing. Outcomes would also include wound infections,
620 costs and quality of life. It would require that the number of
621 applications of the debridement technique would need to
622 reflect the number of applications required in clinical
623 practice, rather than having the trial restricted to a fixed
624 number. The RCT that is currently ongoing is not helpful in
625 this respect because the protocol has no mention of time to
626 healing as an outcome measure or of wound infection rates
627 [42]. Also, an audit of current debridement practice in
628 community health practice in the UK would be very
629 helpful.30
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